Get the Stockscreener App
46.13
0.09%
-0.04
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Qiagen Nv stock is traded at $46.13, with a volume of 2.00M.
It is down -0.09% in the last 24 hours and up +7.53% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$46.17
Open:
$46.59
24h Volume:
2.00M
Relative Volume:
1.06
Market Cap:
$9.53B
Revenue:
$2.10B
Net Income/Loss:
$402.17M
P/E Ratio:
23.83
EPS:
1.9357
Net Cash Flow:
$403.87M
1W Performance:
+1.65%
1M Performance:
+7.53%
6M Performance:
+12.62%
1Y Performance:
-4.16%
1-Day Range:
$45.97
$46.75
1-Week Range:
$44.95
$46.75
52-Week Range:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, NTRA, A, IDXX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
46.13 | 9.53B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
690.00 | 255.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
229.04 | 161.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
393.44 | 56.71B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.97 | 48.77B | 7.23B | 1.41B | 1.09B | 4.979 |
IDXX
Idexx Laboratories Inc
|
560.36 | 44.15B | 4.45B | 1.10B | 1.06B | 13.59 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-26 | Resumed | UBS | Neutral |
| Jul-14-26 | Downgrade | Berenberg | Buy → Hold |
| Jun-25-26 | Initiated | Kepler | Hold |
| Jun-23-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-29-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
QIAGEN N.V. (QIA): BlackRock Discloses 12.91% Voting Rights - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Notes AFM Filing on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. Stock 12‑Month Price Target Raised to $47.5, Implies 7% Upside - TradingView
Qiagen stock gains 0.39 percent after-hours to EUR 40.74 - AD HOC NEWS
Qiagen stock gets a new AI growth story from QIAGEN - AD HOC NEWS
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - BioSpace
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA): BlackRock Notifies 13.04% Voting Rights - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Receives AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Discloses BlackRock 12.90% Voting Rights - TradingView
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - Business Wire
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
Qiagen NV (CEUX:QIAD) Shiller PE Ratio : (As of Oct. 03, 2026) - GuruFocus
QIAGEN N.V. (QIA): Bank of America Holds 4.95% Voting Rights - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) AFM Discloses Bank of America Voting Rights Notice - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN jumps as new FDA clearance bolsters its syndromic-testing growth story - Quiver Quantitative
Qiagen (NYSE:QGEN) Shares Climb 7.7%What's Next? - MarketBeat
Qiagen gains on report talks with potential buyer have advanced (QGEN:NYSE) - Seeking Alpha
Qiagen N.V. (1QGEN.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel - Yahoo Finance UK
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel - TradingView
A Look at Qiagen NV (QGEN) After 3.9% Decline -- GF Value $49.92 vs Price $42.04 - GuruFocus
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
QIAGEN N.V. (QIA) Notified of Bank of America Voting Rights Filing - TradingView
QIAGEN N.V. (QIA): Bank of America Discloses 5.15% Holding - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Notes AFM Filing on Voting Rights Change - TradingView
QIAGEN N.V. (QIA): Bank of America At 5.15% Stake - TradingView
QIAGEN N.V. (QIA) Discloses BlackRock Voting Rights Notification - TradingView
QIAGEN N.V. (QIA): BlackRock Holds 12.97% Voting Rights - TradingView
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM BlackRock Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Reports AFM BlackRock Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Notes AFM Voting Rights Notice by BlackRock - TradingView
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):